Last $21.03 USD
Change Today -0.03 / -0.14%
Volume 90.5K
SGNT On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Open
$20.99
Previous Close
$21.06
Day High
$21.35
Day Low
$20.59
52 Week High
01/6/14 - $26.08
52 Week Low
05/17/13 - $15.71
Market Cap
669.6M
Average Volume 10 Days
191.8K
EPS TTM
$0.71
Shares Outstanding
31.8M
EX-Date
--
P/E TM
29.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGENT PHARMACEUTICALS INC (SGNT)

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Docetaxel, an antineoplastic agent used to treat advanced or metastatic breast cancer after chemotherapy failure; Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2013, its product portfolio included 53 marketed products. It sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

269 Employees
Last Reported Date: 03/7/14
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $329.6K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $307.5K
Executive Vice President of National Accounts...
Total Annual Compensation: $277.6K
Compensation as of Fiscal Year 2012.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 11:20 AM

Sagent Pharmaceuticals, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 11:20 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

Sagent Pharmaceuticals Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2013; Provides Earnings Guidance for 2014

Sagent Pharmaceuticals announced unaudited consolidated earnings results for the fourth quarter and fiscal year ended December 31, 2013. Net revenue for the fourth quarter of 2013 was $64.1 million, an increase of $10.9 million or 20%, compared to $53.2 million in the fourth quarter of 2012. The increase was driven by $13.6 million in revenue from the launch of 31 new codes or presentations of 12 new products since December 2012, partially offset by declines in revenue from existing products. Income from operations was $5 million against loss from operations of $0.043 million prior year period. Income before income taxes was $4.5 million against loss before income taxes of $0.062 million of prior year period. Net income reported was $3.6 million or $0.11 income per share compared to net loss of $0.062 million or $0.00 loss per share of prior year period. EBITDA was $7.7 million against $0.7 million of prior year period. Adjusted EBITDA was $7.124 million against adjusted LBITDA of $2.677 million a year ago. Net revenue for the fiscal year ended December 31, 2013 was $244.8 million, an increase of $61.1 million, or 33%, compared to $183.6 million in fiscal 2012. Income from operations was $31.4 million against loss from operations of $15.5 million of prior year period. Income before income taxes was $30.5 million against loss before income taxes of $16.8 million of prior year period. Net income reported was $29.6 million or $0.99 diluted income per share compared to net loss of $16.8 million or $0.60 loss per share of prior year period. EBITDA was $38.2 million against LBITDA of $10 million of prior year period. Adjusted EBITDA was $40.764 million against adjusted LBITDA of $0.628 million a year ago. The company generated $47.9 million in cash flow from operations during fiscal 2013. The company provided earnings guidance for 2014. The company’s business plan for fiscal 2014 currently anticipates: net revenue for the year to be in the range of $250 to $290 million driven by 10 to 15 product launches. The company anticipates reported net income for fiscal 2014 to be in the range of a $10 million loss to $10 million in earnings. Adjusted gross profit as a percentage of net revenue in the range of 24% to 28%, inclusive of approximately $8 million of incremental expense due to unabsorbed manufacturing costs at SCP facility; product development expense in the range of $30 million to $36 million, which is a $10 million to $16 million increase from 2013, the increase is driven by carryover spending from 2013.

Sagent Pharmaceuticals, Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-12-2014 01:00 PM

Sagent Pharmaceuticals, Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-12-2014 01:00 PM. Venue: The Waldorf Astoria Hotel, New York, New York, United States. Speakers: Jonathon M. Singer, Chief Financial Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $21.03 USD -0.03

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $22.81 USD +0.10
Allergan Inc/United States $133.92 USD +2.46
Endo International PLC $57.26 USD -0.44
Hospira Inc $42.84 USD -0.16
Sun Pharmaceutical Industries Ltd 625.05 INR 0.00
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 21.3x
Price/Sales 2.7x
Price/Book 2.8x
Price/Cash Flow 22.6x
TEV/Sales 2.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.